Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients
Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients.
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
Culmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial
Culmination Bio, a new Intermountain Health Company, and Cofactor Genomics, a predictive diagnostic immunotherapy company, today announced a partnership to leverage samples and data from one of [...]
This collection highlights our most downloaded cancer papers published in 2022. Featuring authors from around the world, these papers showcase valuable research from an international community.
Cofactor Genomics Opens Enrollment for Non-small Cell Lung Cancer Study of OncoPrism Predictive Diagnostic Assay
SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in [...]